Table 6 Changes in ADA.

From: Safety, efficacy, and immunogenicity of a novel IgG degrading enzyme (KJ103): results from two randomised, blinded, phase 1 clinical trials

Visits

Statistics

China

New Zealand

Pre-dose

N

34

34

Median

0

0

Min,Max

0, 1:429.61

0, 1:242.58

D7

N

26

26

Median

0

0

Min,Max

0, 1:408.25

0, 1:246.78

D14

N

26

26

Median

1:1041.97

1:257.50

Min,Max

0, 1:144433.38

0, 1:20855.78

D63

N

24

25

Median

1:605.89

1:158.64

Min,Max

<1:10, 1:10989.27

<1:10, 1:7171.39

D180

N

25

25

Median

1:524.77

1:214.35

Min,Max

0, 1:4921.42

0, 1:5782.43

Back to article page